Mutational spectrum
Reported mutations are mainly point mutations (missense, nonsense, splicing mutations), but also small deletions, duplications and insertions. Large deletions and duplications have also been described and have become more accessible through diagnostic techniques such as MLPA and array-CGH. Variants identified in each Usher gene are continuously registered in LOVD-USHbases. 4 1.6 Analytical methods Several strategies can be used and have different detection rates.
(1) Complete Sanger sequencing of coding exons and flanking intronic sequences. (2) For USH1: Initial haplotype analysis can help in preselecting the most likely causative gene. If haplotyping is not an option (lack of additional samples from the family, uninformative constellation), genes should be sequenced in the order of their causal frequency: MYO7A, CDH23, PCDH15, USH1C and USH1G. CLRN1 should be considered if all USH1 genes are negative. (3) For USH2: As in USH1, initial haplotype analysis can help in preselecting the most likely causative gene. The USH2A gene is causative in 70-80% of cases. In cases where linkage analysis is not an option, direct sequencing of USH2A is the reasonable first step. If this turns out to be negative, the six N-terminal DFNB31 (USH2D) exons should be sequenced, then GPR98 (USH2C). CLRN1 should be considered if all USH2 genes are negative. (4) Because founder mutations exist in various populations for several USH genes (USH1C, PCDH15, USH2A, CLRN1), the ethnicity of the patient should be taken into account. (5) In some patients (o10%), it can be necessary to look for large rearrangements. This can be performed by array CGH with customized chips for Usher genes. An MLPA kit is available for PCDH15 and is under development for USH2A. (6) Genotyping microarrays with allele-specific oligonucleotides corresponding to known Usher syndrome-associated sequence variants can be used for simultaneous mutation screening in all USH genes. 5 The approach is comparatively inexpensive, but because many mutations are private, negative screening does not exclude a causative role for the genes represented on the chip. (7) Next-generation sequencing (NGS) will soon allow for largescale sequencing of all USH genes in a patient. Although most labs do not offer this type of analysis yet, it will likely become the standard diagnostic approach in the near future.
Analytical validation
Confirmation of a mutation should be performed by de novo amplification and sequencing from the patient's sample. Segregation analysis within a family is highly recommended to ascertain the parental origin of each identified variant. Special care is required for interpretation if variants of unknown clinical significance are identified, such as missense and translationally silent substitutions (exonic synonymous changes and intronic variations).
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) The frequency has been reported to be 1/25 000 in the United States and Scandinavia. 6 Following new data, the prevalence may be 5 times higher. 7 1.9 If applicable, prevalence in the ethnic group of the investigated person Population-or ethnicity-specific prevalences exist for different subtypes because of founder mutations in certain populations: This is the case for USH3 in Finland and among Ashkenazi Jews, where this subtype accounts for more than 40% of the cases. Some mutations are particularly frequent in specific populations (eg, p.Arg1502X/CDH23 in Swedes; p.Arg245X/PCDH15 in Ashkenazi Jews; c.216G4A/USH1C in Acadians and Quebecois; p.Tyr176X/ CLRN1 in Finns (see LOVD-USHbases)). 4 
Diagnostic setting
Comment: Prenatal diagnosis is rarely requested. Because the hearing deficit can be compensated by hearing aids or, in case of USH1 and sometimes USH3, cochlear implants, requests for prenatal diagnosis should be discussed in detail in genetic counseling. Prenatal diagnosis remains exceptional.
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
More than 90% for USH1.
Around 80% for USH2. USH3: probably more than 90%.
Analytical specificity (proportion of negative tests if the genotype is not present)
100%.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Because of extensive genetic heterogeneity, genetic testing is rarely carried out for all known USH genes in patients who lack mutations in the major genes (this limitation will probably be overcome with the introduction of NGS into molecular genetic testing). If comprehensive analysis was carried out for all known exons, the clinical sensitivity would probably be B80% for USH1 and USH2.
CLRN1 mutations can cause an USH1-or USH2-like phenotype, and USH3 individuals may therefore sometimes not be subjected to CLRN1 testing. Estimation of the clinical sensitivity for USH3 is therefore difficult.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Almost 100%. 8 ), ERG and eye fundoscopy, thyroid function (Pendred syndrome), renal function (Alport syndrome). Genetic testing can help adapt the clinical surveillance (clearly, pathogenic mutations in an Usher gene would justify regular follow-up by ophthalmologists and audiologists, but the other investigations mentioned above would become dispensable). This would unburden the patient, but also save costs for the health-care system.
How is the cost effectiveness of alternative diagnostic methods to be judged?
In deaf children with an up to 10% probability of developing additional retinal degeneration because of Usher syndrome, Sanger sequencing of the major genes for the different Usher subtypes is laborious, but probably less expensive than regular clinical follow-ups by several different disciplines (see Section 3.1.2). With high-throughput simultaneous genotyping, for example, by next-generation sequencing, entering the field of genetic diagnostics, the genetic approach will certainly pay off.
Will disease management be influenced by the result of a genetic test?
3.2 Predictive setting: The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe):
Yes. The audiological and visual handicaps reduce the patient's mobility and narrow the choices regarding professions.
If the test result is negative (please describe): If extensive early genetic testing in a hearing-impaired person has been carried out retinal degeneration in later life is unlikely, making choice of professions that require intact vision an option.
Which options in view of lifestyle and prevention does a person at risk have if no genetic test has been done (please describe)?
All options if hearing is normal. If hearing is congenitally abnormal, Usher syndrome is likely (depending on the genetic distance to the index case) and the restrictions are as said under Section 3.2.1.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked) 3.3.1 Does the result of a genetic test resolve the genetic situation in that family? Yes.
Can a genetic test in the index patient save genetic or other tests in family members?
No. However, (a) normal hearing would make the diagnosis very unlikely and genetic testing unnecessary, (b) congenital hearing impairment could be due to other causes (environmental or genetic, eg, GJB2 mutations), (c) co-occurrence of deafness and retinal degeneration in a close relative would make the presence of the same mutations as in the index patient very likely.
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member? Yes.
Prenatal diagnosis (To be answered if in 1.10 'D' was marked)
Possible when two confirmed deleterious mutations are identified in the family. Rarely requested (see Section 1.10).
Does a positive genetic test result in the index patient enable a prenatal diagnosis?
This depends on the carrier status of the partner. Because numerous variants of unknown clinical significance can be identified in the Usher genes, genetic counseling can be complicated.
Also, the possibility of digenic inheritance should be considered (as has been shown for CDH23/PCDH15 9 and GPR98/PDZD7 10 ). Moreover, alleles in second loci may act as modifiers (as has been shown for heterozygous MYO7A alleles modifying USH3A 11 and heterozygous PDZD7 10 alleles modifying USH2A).
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) For many patients, the knowledge about the genetic defect is valuable in itself. In particular, patients with nonsense mutations could benefit from future translational read-through therapy approaches. 12 Knowledge of the responsible gene and its mutations may give access to future therapies. Moreover, the identification of a mutation excludes differential diagnoses (see Section 3.1).
Parents of children with USH1 may consider training their children in vision-independent modes of communication such as tactile signing.
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